US 12,331,133 B2
Therapeutic antibodies for treating lung cancer
Kevin J. Kramer, Nashville, TN (US); and Ivelin Georgiev, Nashville, TN (US)
Assigned to VANDERBILT UNIVERSITY, Nashville, TN (US)
Appl. No. 17/600,862
Filed by VANDERBILT UNIVERSITY, Nashville, TN (US)
PCT Filed Apr. 3, 2020, PCT No. PCT/US2020/026553
§ 371(c)(1), (2) Date Oct. 1, 2021,
PCT Pub. No. WO2020/206233, PCT Pub. Date Oct. 8, 2020.
Claims priority of provisional application 62/829,503, filed on Apr. 4, 2019.
Prior Publication US 2022/0185911 A1, Jun. 16, 2022
Int. Cl. C07K 16/30 (2006.01); A61P 35/00 (2006.01); C07K 16/22 (2006.01)
CPC C07K 16/3023 (2013.01) [A61P 35/00 (2018.01); C07K 16/22 (2013.01); C07K 16/3092 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01)] 10 Claims
 
1. A recombinant antibody, wherein the antibody comprises a light chain variable region (VL) that comprises a light chain complementarity determining region (CDRL)1, CDRL2, and CDRL3 and a heavy chain variable region (VH) that comprises a heavy chain complementarity determining region (CDRH)1, CDRH2, and CDRH3, wherein the recombinant antibody comprises:
 
 (SEQ ID NO: 1)
 
 CDRH1 is GFTVSSNY,
 
 
 
 (SEQ ID NO: 2)
 
 CDRH2 is IYTGGGT,
 
 
 
 (SEQ ID NO: 3)
 
 CDRH3 is AREAPFTAALYY,
 
 
 
 (SEQ ID NO: 4)
 
 CDRL1 is SSDVG,
 
 
 
 (SEQ ID NO: 5)
 
 CDRL2 is EVT,
 
 and
 
 
 
 (SEQ ID NO: 6)
 
 CDRL3 is SSYAGNNNRVV;
 
 (SEQ ID NO: 7)
 
 CDRH1 is GYIFEAYG,
 
 
 
 (SEQ ID NO: 8)
 
 CDRH2 is ISVFNGDR,
 
 
 
 (SEQ ID NO: 9)
 
 CDRH3 is ATGAELLSAFGV,
 
 
 
 (SEQ ID NO: 10)
 
 CDRL1 is TSNIGAGYE,
 
 
 
 (SEQ ID NO: 11)
 
 CDRL2 is GNT,
 
 and
 
 
 
 (SEQ ID NO: 12)
 
 CDRL3 is QSYDSSRGGFWV;
 
 (SEQ ID NO: 13)
 
 CDRH1 is GFAFSTYV,
 
 
 
 (SEQ ID NO: 14)
 
 CDRH2 is ISHEGSDK,
 
 
 
 (SEQ ID NO: 15)
 
 CDRH3 is AKEGPRDYYYYGWDV,
 
 
 
 (SEQ ID NO: 16)
 
 CDRL1 is SSDVGAYNY,
 
 
 
 (SEQ ID NO: 17)
 
 CDRL2 is EVK,
 
 and
 
 
 
 (SEQ ID NO: 18)
 
 CDRL3 is SSYVRSGTRV;
 
 (SEQ ID NO: 19)
 
 CDRH1 is GGSISSGSYY,
 
 
 
 (SEQ ID NO: 20)
 
 CDRH2 is IYMSGTT,
 
 
 
 (SEQ ID NO: 21)
 
 CDRH3 is ARDPYNWNANYYIDV,
 
 
 
 (SEQ ID NO: 22)
 
 CDRL1 is QGIRND,
 
 
 
 (SEQ ID NO: 23)
 
 CDRL2 is AAS,
 
 and
 
 
 
 (SEQ ID NO: 24)
 
 CDRL3 is LQHNSYPYT;
 
 (SEQ ID NO: 25)
 
 CDRH1 is GFTFSTYV,
 
 
 
 (SEQ ID NO: 26)
 
 CDRH2 is IWYDGSNK,
 
 
 
 (SEQ ID NO: 27)
 
 CDRH3 is ARDAGSDAFDI,
 
 
 
 (SEQ ID NO: 28)
 
 CDRL1 is QSISSY,
 
 
 
 (SEQ ID NO: 29)
 
 CDRL2 is AAS,
 
 and
 
 
 
 (SEQ ID NO: 30)
 
 CDRL3 is QQSYSTPAT;
 
 (SEQ ID NO: 31)
 
 CDRH1 is GFPFSNYW,
 
 
 
 (SEQ ID NO: 32)
 
 CDRH2 is ISGDGSST,
 
 
 
 (SEQ ID NO: 33)
 
 CDRH3 is ARVQLLADDVLDI,
 
 
 
 (SEQ ID NO: 34)
 
 CDRL1 is QSVYANH,
 
 
 
 (SEQ ID NO: 35)
 
 CDRL2 is GAS,
 
 and
 
 
 
 (SEQ ID NO: 36)
 
 CDRL3 is QQYGRSPLT;
 
 (SEQ ID NO: 37)
 
 CDRH1 is GGIVHSYS,
 
 
 
 (SEQ ID NO: 38)
 
 CDRH2 is VVPVFDTR,
 
 
 
 (SEQ ID NO: 39)
 
 CDRH3 is GRLTYHYDSSGFVSTVGNALDV,
 
 
 
 (SEQ ID NO: 40)
 
 CDRL1 is QSVTNIY,
 
 
 
 (SEQ ID NO: 41)
 
 CDRL2 is GAS,
 
 and
 
 
 
 (SEQ ID NO: 42)
 
 CDRL3 is HQYGSSPQT.